

This is an Accepted Manuscript for Epidemiology & Infection. Subject to change during the editing and production process.

DOI: 10.1017/S095026882400181X

1 **Trends in general practitioner consultations for hand foot and mouth disease in**
2 **England between 2017 and 2022**

3 Natalia G. Bednarska¹, Sue Smith¹, Megan Bardsley¹, Paul Loveridge¹, Rachel Byford²,
4 William Elson², Helen Hughes¹, Simon de Lusignan^{2,3}, Dan Todkill¹ and Alex J. Elliot^{1*}

5 ¹ Real-time Syndromic Surveillance Team, Field Services, UK Health Security Agency,
6 Birmingham, United Kingdom

7 ² Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford United
8 Kingdom

9 ³ Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC),
10 RCGP, Euston Square, London, United Kingdom.

11 ***Corresponding author:** Alex J. Elliot, Real-time Syndromic Surveillance Team, Field
12 Services, 23 Stephenson Street, Birmingham B2 4BH. Alex.elliott@ukhsa.gov.uk; 44 121 232
13 9211

14 **Key words:** Hand, foot and mouth disease; general practitioner; syndromic surveillance;
15 Enterovirus; Coxsackievirus

16

This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.

17 **Abstract**

18 Hand foot and mouth disease (HFMD) is a contagious communicable disease, with a high
19 incidence in children aged under 10 years. It is a mainly self-limiting disease but can also
20 cause serious neurological or cardiopulmonary complications in some cases, which can lead
21 to death. Little is known about the burden of HFMD on primary care health care services in
22 the UK. The aim of this work was to describe trends in general practitioner (GP)
23 consultations for HFMD in England from January 2017 to December 2022 using a syndromic
24 surveillance network of GPs. Daily GP consultations for HFMD in England were extracted
25 from 1 January 2017 to 31 December 2022. Mean weekly consultation rates per 100,000
26 population and 95% confidence intervals (CI) were calculated. Consultation rates and rate
27 ratios (RR) were calculated by age group and sex. During the study period, the mean weekly
28 consultation rate for HFMD (per 100,000 registered GP patients) was 1.53 (range of 0.27 to
29 2.47). In England, children aged 1-4 years old accounted for the largest affected population
30 followed by children <1 years old. We observed a seasonal pattern of HFMD incidence
31 during the non-COVID years, with a seasonal peak of mean weekly rates between months of
32 September and December. HFMD is typically diagnosed clinically rather than through
33 laboratory sampling. Therefore, ability to look at the daily HFMD consultation rates provides
34 excellent epidemiological overview on disease trends. The use of a novel GP-in hours
35 surveillance system allowed a unique epidemiological insight into the recent trends of general
36 practitioner consultations for HFMD. We demonstrate a male predominance of cases, the
37 impact of the non-pharmaceutical interventions during the COVID-19 pandemic, and a
38 change in the week in which the peak number of cases happens post pandemic.

39

40 **Introduction**

41 Hand foot and mouth disease (HFMD) is a contagious communicable disease, with most
42 cases diagnosed in children aged under 10 years [1]. HFMD was first diagnosed in Toronto,
43 Canada, in 1957, but subsequent work recognised the global endemic nature of HFMD. The
44 etiological agents responsible for HFMD belong to non-polio enterovirus family, including
45 Enteroviruses (EV) and Coxsackieviruses (CV) [1]. EV are classified genetically into four
46 categories (A-D) and CV into two groups CV-A and CV-B. Historically, the most common
47 global causes of HFMD were EV-A71 and CVA16, however, currently a higher proportion of
48 HFMD outbreaks are caused by other EVs such as CVA6 and CVA10 [2].

49 Clinical diagnosis of HFMD is typically based on an assessment of the early presenting
50 symptoms of HFMD, including fever, malaise, loss of appetite, cough and abdominal pain.

51 Early symptoms are followed by ulcerative lesions of the oral cavity within 1-2 days and
52 classically the presentation of macules and papules of hands and feet appearing later [3].

53 Atypical manifestations of HFMD (and EV infections in general) can present, particularly in
54 adults, which include future sites for skin manifestations (including the scalp, buttocks and
55 genitalia) and persisting non-dermatological symptoms such as sore throat, fever and asthenia
56 [4, 5]. The incubation period of HFMD is dependent on the serotype of the causative

57 pathogen as well as age group of the patient, but multiple studies estimated the incubation
58 period to be around 4-8 days, allowing asymptomatic spread of disease in the community [6].

59 Spread of HFMD can be person-to-person via the faecal-oral route, airborne via infected
60 droplets spread through sneezing or coughing or through contaminated fomites [2]. General
61 infection control measures include frequent handwashing and avoiding close contact with
62 infected individuals, which might be difficult to implement in certain settings such as
63 nurseries.

64 There is no specific treatment for HFMD other than pain relief management [1]. The disease
65 is usually self-limiting, however, in a small proportion of cases the disease can lead to
66 neurological complications, respiratory failure and in some cases death [7]. Globally,
67 countries in the Asia-Pacific region deal with the highest burden of HFMD, where it is
68 estimated to cause 96,900 (95% CI 40 600 to 259 000) age-weighted disability-adjusted life
69 years per annum [8].

70 Different causative agents of HFMD can result in more severe outcomes; enterovirus EV-
71 A71 has been known for its virulence, with more severe symptoms including meningitis,
72 encephalitis, and pneumonia [3]. While HFMD is in general a self-limiting mild disease,
73 there is a higher risk of more severe disease occurring in infants younger than 6 months and
74 immunocompromised individuals [9]. In a small proportion of cases, fatal neurological or
75 cardiopulmonary complications can occur. There have also been reports of post-infection
76 neurological sequelae in patients who have recovered from severe infection [10].

77 In England there is limited epidemiological information about the community burden of
78 HFMD as the disease is not required by the law to be reported. Previous epidemiological
79 studies have shown that HFMD seasonality in England occurs in late summer to early
80 autumn, either sporadically or in regular outbreaks [11]. Meteorological parameters have
81 shown a significant association with the incidence of HFMD in subtropical regions, including
82 mean temperature, rainfall, and relative humidity [12, 13]. Modelling results by a South
83 Korean research group illustrated direct correlation of the HFMD incidence rate with average
84 temperature and relative humidity [14], therefore the disease potentially has more public
85 health relevance in the context of global warming.

86 Most HFMD outbreaks happen in childcare centres, nurseries, or within the family setting,
87 since HFMD affects mostly children younger than 10 years of age. CVA16 was the main

88 pathogen of HFMD outbreaks in England in 1959 and 1994 [11, 15]. Here, we use routinely
89 available general practitioner (GP) HFMD consultation data to provide an updated
90 epidemiological summary of HFMD burden on GP practices in England.

91

92 **Methods**

93 **Study design and population**

94 This was a retrospective, observational, descriptive analysis of GP consultations for HFMD
95 across England. GP consultation data were sourced from the UK Health Security Agency
96 (UKHSA) GP in-hours syndromic surveillance system. The GP in-hours system collates and
97 monitors GP consultation data for a range of health conditions and diseases as part of the
98 routine UKHSA real-time syndromic surveillance programme [16]. The GP in-hours system
99 uses data from two separate sources [17]. Here, GP in-hours consultations were used from the
100 Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), one
101 of the world's oldest sentinel networks. RSC data are held on the Oxford- Clinical
102 Informatics Digital Hub (ORCHID) [18]. The study population was all persons who
103 presented to general practices of the RSC [16] between 01 January 2017 to 31 December
104 2022 inclusive. The mean number of general practices across the period of the study
105 was 1,245 practices across England covering a patient population of 11 million [19]. The
106 study dataset included information on primary care demographics such as age and sex.

107 **Case definition**

108 A case of HFMD was defined as a general practice consultation episode where the GP
109 assigned a Systematized Nomenclature of Medicine Clinical Terms (SNOMED) clinical term
110 (the terminology system currently used in the UK practice) inferring a diagnosis of HFMD
111 [20]. The SNOMED clinical terms included for HFMD were as follows: 67171006

112 Enteroviral vesicular stomatitis with exanthem; 154357002 Hand foot and mouth disease;
113 175497008 Hand, foot and mouth disease; 186664000 (Hand, foot & mouth disease) or
114 (vesicular stomatitis with exanthem); and 266108008 Enteroviral vesicular stomatitis with
115 exanthem.

116 **Statistical analysis**

117 Daily counts of GP consultations for HFMD and the GP registered practice population were
118 extracted for each day during the study period by age group and sex from 1 January 2017 to
119 31 December 2022 inclusive.

120 The weekly HFMD consultation rate (and 95% confidence intervals; CI) per 100,000
121 population across England was calculated using the count of HFMD consultations per
122 International Standards Organisation (ISO) week as the numerator and the weekly GP
123 registered population as the denominator. Bank holidays and weekends were removed from
124 the analysis as routine in-hours GP services are largely restricted on these days. The annual
125 HFMD rates were calculated using the annual total count as numerator and the annual mean
126 population as denominator.

127 Time series graphs were used to visualise trends and seasonality of the weekly national
128 consultation rates for HFMD, overall and stratified by age group and sex. Incidence was
129 defined as the total number of HFMD cases divided by the average population size during the
130 study period.

131

132 **Results**

133 **Demographic and temporal characteristics**

134 The cumulative sum of HFMD consultations reported through the GP in-hours system in
135 England from 01 January 2017 to 31 December 2022 was 76,386, translating to a mean

136 weekly rate across the whole study period of 2.15 HFMD consultations per 100,000
137 registered population.

138 Distinct seasonal HFMD activity was observed across the study period (Figure 1). During
139 'pre-COVID-19 pandemic years (2017-2019), peak HFMD activity (all ages) occurred at
140 weeks 43 and 44, with seasonal activity increasing from baseline activity at week 35-36 until
141 peaking approximately 8 week later. Peak seasonal activity also varied across the pre-
142 pandemic years; 2017 and 2018 peaked at 8.6 and 9.9 consultations per 100,000 while 2019
143 had a lower peak at 6.3 per 100,000 (Table 1).

144 During the COVID-19 pandemic years (2020 and 2021), the HFMD consultation rate
145 dropped immediately after the first announcement of COVID-19 restrictions in week 11
146 (early March) 2020. During 2020 there was no obvious typical epidemic activity or peak
147 observed. The very low HFMD weekly rate continued through 2021 until approximately
148 week 26, when activity started to increase and then increased sharply from week 35, peaking
149 higher (10.5 consultations per 100,00) and earlier (week 41) than other study years (Figure
150 1).

151 During the post-pandemic year (2022), HFMD seasonal activity resumed expected trend,
152 with mean weekly rates higher than 2020 and 2021 however lower than pre-pandemic years
153 (Table 1). During 2022, the seasonal peak of HFMD activity started later and peaked lower
154 than previous years. The timing of the 2022 seasonal peak was also later than other study
155 years; 2022 peak activity occurred at week 46, however activity remained high until week 49
156 when it then decreased, then following expected seasonal trends.

157 **Figure 1. Weekly incidence rate of hand foot and mouth disease (HFMD) per 100,000**
158 **population (all ages), England 2017-2022**

159 **Table 1: Hand foot and mouth disease (HFMD) seasonal activity range**

160 When stratified by age, the highest rates of consultations for HFMD in England were
161 observed in children aged 1 to 4 years, followed by infants younger than 1 year old (Table 2).
162 During the whole study period we had registered the total of 76,386 HFMD GP consultations.
163 The average annual consultation rate for the whole study period was 112.1 per 100,000
164 registered population. Annually HFMD consultation rates in children aged 1 to 4 and <1 year
165 were the highest in year 2018 (with a peak of 2,411.5 and 1,799.9 per 100,000, respectively).
166 Activity in age groups 5 years and older was much lower with insignificant activity in adults
167 aged 45 years and over (Table 2).

168 Temporally, seasonal trends in HFMD incidence across individual age groups generally
169 followed national 'all ages' trends (Figures 1 and 2). For children aged <1 year, rates
170 observed during in 2018 were higher than other years, however, for 1-4 years age group, the
171 highest rates were observed in 2021. Also of note, during 2021 the seasonal peak of HFMD
172 occurred earlier in the 1-4 years age group (compared to <1 years) but was seen to peak later
173 during 2022 (Figure 2). There was also evidence of a possible lag between younger and older
174 age groups, with HFMD consultation activity in adults aged 45 years and over appearing to
175 start and finish later than activity in younger children by a few weeks. However, the small
176 number of HFMD consultations reported in older adults made comparisons challenging.

177 When stratified by gender, HFMD consultation rate for males was higher than that seen in
178 females, with the rate ratio consistently illustrating male rates were 20% higher than female
179 across each year of the study period (Table 2).

180 **Table 2. Epidemiological characteristics of GP consultations for hand foot and mouth**
181 **disease (HFMD) in England, 2017-2022, presented as the annual number of HFMD GP**
182 **consultations (annual incidence rate per 100,000).** Post Covid-19 pandemic years are
183 highlighted in grey.

184 **Figure 2. Weekly GP consultation rate of hand foot and mouth disease (HFMD) per**
185 **100,000 population by age group in England (2017-2022).**

186

187 **Discussion**

188 This study provides an update on recent epidemiological trends in general practice
189 consultations for HFMD in England. Here, we use a national general practice syndromic
190 surveillance system that is routinely used to report on all-hazards including infectious
191 diseases (e.g. influenza, COVID-19), environmental impacts (e.g. heatwaves), mass
192 gatherings (e.g. large sporting events) and chemical incidents (e.g. large industrial fires).
193 Laboratory testing and confirmation of HFMD in England is rare and therefore these GP
194 consultation data are a useful proxy for HFMD incidence and can contribute to surveillance
195 of the disease in England. Our study thereby provides a valuable insight into the
196 epidemiology and burden of this disease. The data presented here show that HFMD peak
197 week occurred during week 43 or 44 pre pandemics, During the years 2017-2019 mean
198 weekly rates ranged from 2.03 to 2.47 per 100,000 registered patients. Our data clearly shows
199 seasonality of HFMD infections for children between 1 and 14 years of age, with highest
200 incidence during months September to January, coinciding with return of schools following
201 the summer holiday.

202 Our study shows that the burden of HFMD mainly occurred in children under 5 years of age,
203 which is supported by existing evidence [2, 21-23]. We also demonstrated higher consultation
204 rates in males versus females (average rate ratio of 1.2 during the studied period of time),
205 however our data support global epidemiological reports where similar findings were made
206 [24, 25]. A research study on transmissibility of HFMD viruses showed higher indices for
207 male transmissibility and infection rates [26]. The explanation suggested elsewhere in the

208 literature for this phenomenon was the fact that male children are generally more active and
209 exposed to the environment than females [27]. The predominance of disease in younger
210 males is also reported for other conditions, such as asthma, where it has been shown that
211 asthma incidence, prevalence and hospitalization rates are higher in pre-pubertal boys than
212 girls of the same age, but this trend reverses during adolescence [28, 29].

213 The current study period spans the COVID-19 pandemic. The impact of the pandemic on the
214 epidemiology of HFMD is clear from our results. GP consultations for HFMD decreased
215 during the early part of 2020, diverging from the seasonal trend observed in other years.
216 Consultation rates remained at very low (near ‘zero’) levels until week 25 of 2021, when
217 HFMD consultations slowly started to increase and return to expected levels. This
218 observation is consistent with reports of the impact of COVID-19 on the circulation of other
219 infectious diseases. In England, non-pharmaceutical interventions (NPIs) were introduced to
220 control the spread of SARS-CoV-2 in the community [30]. An indirect effect of NPIs was the
221 interruption of the transmission chain of other infectious diseases. During the pandemic,
222 surveillance data for respiratory syncytial virus, influenza and gastrointestinal pathogens
223 illustrated very low and out-of-season activity [31]. Our findings support that infection
224 control measures for HFMD (hand washing, restricting close contact, removing cases from
225 close contact settings such as nurseries) are effective measures as the impact of NPIs clearly
226 demonstrated a significant decrease in HFMD circulation. However, it must also be
227 considered that other confounders might have played a role, including changes in the
228 availability of health care services and changes in health care seeking behaviour of the public
229 which were also documented during the pandemic [32-34]. Post-pandemic, HFMD
230 seasonality appeared to change. During 2021, the HFMD epidemic curve was earlier than
231 previous years, by 2-3 weeks. However, the following year (2022) saw later activity, 2-3
232 weeks later than expected. The first HFMD season post pandemic (2021) might have seen an

233 earlier surge in cases since the lifting of restrictions resulted in schools returning. The cohort
234 of children in the 1-4 years age group would also contain some children not exposed to
235 HFMD pre-pandemic. This is supported by the finding that the 1-4 years age group had the
236 highest incidence during 2021. Further routine surveillance of HFMD is required over the
237 coming years to establish whether the seasonality of HFMD returns to regular pre-pandemic
238 trends.

239 There was a significant gap since the last epidemiological description of HFMD activity in
240 England, with the last publication dated in 1996 [11]. Hereby, we have provided the first
241 update of HFMD epidemiology for 25 years, presenting trends over the recent years 2017-
242 2022. The original 1996 study by Bendig and Fleming utilised a small sentinel network of
243 GPs, the RCGP Weekly Returns Service [11]. This network consisted of 92 sentinel GP
244 practices covering a mean sample population of 614,303 patients. The GP syndromic
245 surveillance system used in our current study involves the same RCGP surveillance network,
246 however the size of the network and patient population has increased significantly to 1,160
247 practices, with a mean sample registered patient population of 11 million in 2022 [19],
248 thereby providing a much greater and representative sample of the population [35].

249 The peak of HFMD activity described in the 1996 study occurred during ISO week 49, with a
250 peak incidence rate reported at 12.6 consultations per 100,000 population. We present HFMD
251 activity peaking between weeks 41-46 with the maximum mean weekly rate of 10.52 in year
252 2021. The suggestion of a lag in HFMD activity between the youngest and oldest age groups
253 is supported by transmission studies of other communicable diseases between these age
254 groups, particularly acute respiratory infections including those caused by respiratory
255 syncytial virus (RSV) [36, 37]. This merits further research into HFMD transmission as there
256 are potentially important implications for infection control advice for older adults who are
257 more at risk of developing severe disease and complications from HFMD, particularly if they

258 are living with or having close contact with younger children who are in the nursery or school
259 setting and therefore more likely to have exposure to the viruses causing HFMD.

260 Globally the burden and severity of HFMD differs, with particular impact seen in South-East
261 Asian countries, however in comparison there is a lower burden and relative severity of
262 HFMD in England. Particular strains of enterovirus and coxsackievirus display different
263 neurotropic and deadly propensities worldwide and therefore the surveillance of virus and
264 clinical presentation is of vital importance. In Singapore, HFMD was listed as the top 5 most
265 contagious febrile viral illness amongst children below age of 5 years [38]. Some of the
266 clinical manifestations for HFMD viruses include more severe aseptic meningitis,
267 encephalitis, acute flaccid paralysis and flaccid myelitis [39]. Coxsackievirus serotype A6
268 (CVA6) has been identified as a causative agent of autumn 2008 epidemic outbreak of
269 HFMD in Finland, with atypical symptom of onychomadesis as a hallmark of this outbreak
270 [40]. HFMD outbreaks are very common in East Asian countries, where now specific
271 reporting systems are implemented as a control measure. Coxsackievirus CV-A16 continues
272 to evolve into more diverse branches as per epidemiological information provided by a
273 Chinese reporting system [41].

274 In Malaysia, a 1997 outbreak of HFMD resulted in several deaths, after which the country
275 introduced its first control policies including mandatory notification of clusters of cases.
276 Preventative measures inclusive of routine checks of temperature, soles of feet and mouth
277 before allowing children to enter nurseries are also part of the anti HFMD practice in some
278 countries [3]. In the United States of America it has been shown that individual serotypes
279 have different temporal patterns of circulation and often are associated with different clinical
280 manifestations [42]. Moreover, the changes in circulating serotypes might be accompanied by
281 large-scale outbreaks, therefore monitoring HFMD occurrence is of high importance.

282 The serotype EV-A71 was associated with the most infections in Europe, East and South-East
283 Asia. Both Coxsackievirus types A16 (CV-A16) and A6 (CV-A6) are found to be prevalent
284 in USA, Europe [40] and Asia- Pacific with a high pandemic potential [43]. According to
285 historical data only some sporadic outbreaks were recorded elsewhere to be associated with
286 CV-A10 [44, 45].

287 A key strength of our study is that we have utilised one of the only routinely available
288 sources of HFMD clinical data. The GP surveillance network is large and covers
289 approximately 18% of the England population. The network has been shown to be
290 representative of the England population thereby ensuring that we have a good cross-section
291 of the population [19]. This system is routinely used for real-time all-hazard surveillance in
292 England and therefore the clinical diagnosis codes used in this study to identify HFMD
293 consultations can be directly applied prospectively for real-time surveillance of HFMD.
294 However, HFMD cases reported here are likely to be an underestimate of total cases in the
295 community. It is likely that mild or asymptomatic HFMD cases will not report to primary
296 care or may present to other areas of the National Health Service (NHS) in England.
297 Furthermore, before the development of a classic HFMD vesicular rash, the disease can
298 present with relatively generic symptoms in the early stages of infection meaning that a
299 clinical diagnosis made by a GP might not initially indicate HFMD as the causative diagnosis
300 furthering this underestimate. Finally, a range of other pathogens can be responsible for
301 causing typical and atypical manifestations that might cause a differential diagnosis of
302 HFMD [4].

303 Increased public awareness of HFMD and emphasising preventative measures such as basic
304 hygiene remain the best means for preventing and controlling cases and outbreaks of HFMD.
305 In England, NHS and local health protection services advise health professionals
306 encountering cases of HFMD to provide advice to patients and their carers, but that no further

307 specialised health protection advice is required [46]. As the majority of cases are not
308 sampled, nor is this a notifiable disease, syndromic surveillance provides a useful tool for
309 measuring the healthcare burden associated with HFMD.

310 In conclusion, we have described trends in GP consultations for HFMD in England from
311 January 2017 to December 2022 using a syndromic surveillance network of GPs. We
312 observed seasonality of HFMD incidence during the non-COVID years, with a peak of mean
313 weekly rates between months of September and December. Our data shows that in England,
314 children aged 1-4 years old accounted for the largest affected population followed by children
315 <1 years old. This study shows that syndromic surveillance GP reporting on a near-real time
316 basis can provide a valuable insight into HFMD epidemiology. The experiences and lessons
317 learnt from other countries where large outbreaks have occurred (including virulent strains
318 and therefore more severe presentations and increased mortality) highlights the importance of
319 understanding the evolving aetiology of HFMD, epidemiology and changing burden of
320 clinical cases. We have shown that monitoring changes in HFMD epidemiology through
321 prospective surveillance can also provide timely alerts in the event of increasing activity both
322 at national, regional or local level that might implicate changes in the underlying aetiology of
323 cases. Our data provides the framework for assessing changes in healthcare presentation
324 linked to future changes in presenting severity of cases.

325 **Data availability statement.** Applications for requests to access relevant anonymised data
326 included in this study should be submitted to the UKHSA Office for Data Release
327 ([https://www.gov.uk/government/publications/accessing-ukhsa-protected-data/accessing-](https://www.gov.uk/government/publications/accessing-ukhsa-protected-data/accessing-ukhsa-protected-data)
328 [ukhsa-protected-data](https://www.gov.uk/government/publications/accessing-ukhsa-protected-data/accessing-ukhsa-protected-data)).

329 **Author contribution.** Conceptualization, DT, AJE; resources, AJE; data curation, NGB, PL,
330 RB, HH; formal analysis, NGB, MB, HH, DT; investigation, NGB, MB; methodology, NGB,

331 MB, HH; supervision, DT, AJE; validation, NGB, PL, HH, DT, AJE; visualization, NGB,
332 HH, DT; writing - original draft, NGB, DT, AJE; writing - review & editing, all authors.

333 **Acknowledgements.** We thank the Oxford-Royal College of General Practitioners Research
334 and Surveillance Centre, and to its member general practices and their patients who share
335 data with the surveillance system. We also thank the UKHSA Real-time Syndromic
336 Surveillance Team for technical support. DT and AJE are affiliated with the National Institute
337 for Health and Care Research (NIHR) Health Protection Research Unit (HPRU) in
338 Emergency Preparedness and Response at King's College London. AJE is affiliated with the
339 NIHR HPRU in Gastrointestinal Infections at the University of Liverpool. The views
340 expressed are those of the authors and not necessarily those of the NIHR, the UKHSA or the
341 Department of Health and Social Care.

342 **Funding statement.** The research was funded through UKHSA core activities. This research
343 received no external funding.

344 **Competing interests.** The authors declare no conflict of interests.

345

346 References

- 347 [1] **Esposito S and Principi N** (2018) Hand, foot and mouth disease: current knowledge
348 on clinical manifestations, epidemiology, aetiology and prevention. *European Journal*
349 *of Clinical Microbiology and Infectious Diseases* **37**, 391-398.
- 350 [2] **Zhu P, et al.** (2023) Current status of hand-foot-and-mouth disease. *Journal of*
351 *Biomedical Science* **30**, 15.
- 352 [3] **Siegel K, Cook AR and La H** (2017) The impact of hand, foot and mouth disease
353 control policies in Singapore: a qualitative analysis of public perceptions. *Journal of*
354 *Public Health Policy* **38**, 271-287.

- 355 [4] **Drago F, et al.** (2021) Oral and cutaneous manifestations of viral and bacterial
356 infections: not only COVID-19 disease. *Clinics in Dermatology* **39**, 384-404.
- 357 [5] **Second J, et al.** (2017) Clinicopathologic analysis of atypical hand, foot, and mouth
358 disease in adult patients. *Journal of the American Academy of Dermatology* **76**, 722-
359 729.
- 360 [6] **Yang Z, et al.** (2017) Estimating the incubation period of hand, foot and mouth
361 disease for children in different age groups. *Scientific Reports* **7**, 16464.
- 362 [7] **Antona D, et al.** (2016) Severe paediatric conditions linked with EV-A71 and EV-
363 D68, France, May to October 2016. *Eurosurveillance* **21**, pii=30402.
- 364 [8] **Koh WM, et al.** (2018) Severity and burden of hand, foot and mouth disease in Asia:
365 a modelling study. *BMJ Global Health* **3**, e000442.
- 366 [9] **Tan YW and Chu JJH** (2021) Protecting the most vulnerable from hand, foot, and
367 mouth disease. *Lancet Infectious Diseases* **21**, 308-309.
- 368 [10] **Kim B, et al.** (2018) Factors associated with severe neurologic complications in
369 patients with either hand-foot-mouth disease or herpangina: A nationwide
370 observational study in South Korea, 2009-2014. *PLoS One* **13**, e0201726.
- 371 [11] **Bendig JW and Fleming DM** (1996) Epidemiological, virological, and clinical
372 features of an epidemic of hand, foot, and mouth disease in England and Wales.
373 *Communicable Disease Report. CDR Review* **6**, R81-86.
- 374 [12] **Jiang Y, et al.** (2021) Association between meteorological parameters and Hand,
375 Foot and Mouth Disease in mainland China: a systematic review and meta-analysis.
376 *Iranian Journal of Public Health* **50**, 1757-1765.
- 377 [13] **Huang Z, et al.** (2019) Seasonality of the transmissibility of hand, foot and mouth
378 disease: a modelling study in Xiamen City, China. *Epidemiology and Infection* **147**,
379 e327.

- 380 [14] **Kim BI, et al.** (2016) Effect of climatic factors on Hand, Foot, and Mouth Disease in
381 South Korea, 2010-2013. *PLoS One* **11**, e0157500.
- 382 [15] **Alsop J, Flewett TH and Foster JR** (1960) "Hand-foot-and-mouth disease" in
383 Birmingham in 1959. *BMJ (Clinical Research Ed.)* **2**, 1708-1711.
- 384 [16] **de Lusignan S, et al.** (2021) Influenza and respiratory virus surveillance, vaccine
385 uptake, and effectiveness at a time of cocirculating COVID-19: protocol for the
386 English primary care sentinel system for 2020-2021. *JMIR Public Health and*
387 *Surveillance* **7**, e24341.
- 388 [17] **Bardsley M, et al.** (2023) The epidemiology of chickenpox in England, 2016-2022:
389 an observational study using general practitioner consultations. *Viruses* **15**, 2163.
- 390 [18] **de Lusignan S, et al.** (2020) The Oxford Royal College of General Practitioners
391 Clinical Informatics Digital Hub: protocol to develop extended COVID-19
392 surveillance and trial platforms. *JMIR Public Health and Surveillance* **6**, e19773.
- 393 [19] **Smith S, et al.** (2023) New developments and expansion of the GP in-hours
394 syndromic surveillance system: collaboration between UKHSA and the Oxford-Royal
395 College of General Practitioners Clinical Informatics Digital Hub. *British Journal of*
396 *General Practice* **73**, bjgp23X734289.
- 397 [20] **de Lusignan S** (2005) Codes, classifications, terminologies and nomenclatures:
398 definition, development and application in practice. *Informatics in Primary Care* **13**,
399 65-70.
- 400 [21] **Wang Y, et al.** (2020) Epidemiological and clinical characteristics of severe hand-
401 foot-and-mouth disease (HFMD) among children: a 6-year population-based study.
402 *BMC Public Health* **20**, 801.
- 403 [22] **Mirand A, et al.** (2021) A large-scale outbreak of hand, foot and mouth disease,
404 France, as at 28 September 2021. *Eurosurveillance* **26**, pii=2100978.

- 405 [23] **Cabrerizo M, et al.** (2014) Molecular epidemiology of enterovirus 71,
406 coxsackievirus A16 and A6 associated with hand, foot and mouth disease in Spain.
407 *Clinical Microbiology and Infection* **20**, O150-O156.
- 408 [24] **Peng D, et al.** (2020) Epidemiological and aetiological characteristics of hand, foot,
409 and mouth disease in Sichuan Province, China, 2011–2017. *Scientific Reports* **10**,
410 6117.
- 411 [25] **Wang YR, et al.** (2013) Epidemiology and clinical characteristics of hand foot, and
412 mouth disease in a Shenzhen sentinel hospital from 2009 to 2011. *BMC Infectious*
413 *Diseases* **13**, 539.
- 414 [26] **Liao Y, et al.** (2019) Relative transmissibility of hand, foot and mouth disease from
415 male to female individuals. *Epidemiology and Infection* **147**, e284.
- 416 [27] **Wang W, et al.** (2023) Epidemiological characteristics and spatiotemporal patterns of
417 hand, foot, and mouth disease in Hubei, China from 2009 to 2019. *PLoS One* **18**,
418 e0287539.
- 419 [28] **Fuhlbrigge AL, Jackson B and Wright RJ** (2002) Gender and asthma. *Immunology*
420 *and Allergy Clinics of North America* **22**, 753-789.
- 421 [29] **Green MS** (1992) The male predominance in the incidence of infectious diseases in
422 children: a postulated explanation for disparities in the literature. *International*
423 *Journal of Epidemiology* **21**, 381-386.
- 424 [30] **Bernal JL, et al.** (2021) The impact of social and physical distancing measures on
425 COVID-19 activity in England: findings from a multi-tiered surveillance system.
426 *Eurosurveillance* **26**, 2001062.
- 427 [31] **Bardsley M, et al.** (2023) Epidemiology of respiratory syncytial virus in children
428 younger than 5 years in England during the COVID-19 pandemic, measured by

- laboratory, clinical, and syndromic surveillance: a retrospective observational study. *Lancet Infectious Diseases* **23**, 56-66.
- [32] **Murphy M, et al.** (2021) Implementation of remote consulting in UK primary care following the COVID-19 pandemic: a mixed-methods longitudinal study. *British Journal of General Practice* **71**, e166-e177.
- [33] **Eapen V, et al.** (2021) “Watch Me Grow- Electronic (WMG-E)” surveillance approach to identify and address child development, parental mental health, and psychosocial needs: study protocol. *BMC Health Services Research* **21**, 1240.
- [34] **Ferraro CF, et al.** (2021) Describing the indirect impact of COVID-19 on healthcare utilisation using syndromic surveillance systems. *BMC Public Health* **21**, 2019.
- [35] **Leston M, et al.** (2022) Representativeness, vaccination uptake, and COVID-19 clinical outcomes 2020-2021 in the UK Oxford-Royal College of General Practitioners Research and Surveillance Network: cohort profile summary. *JMIR Public Health and Surveillance* **8**, e39141.
- [36] **Korsten K, et al.** (2022) Contact with young children increases the risk of respiratory infection in older adults in Europe - the RESCEU Study. *Journal of Infectious Diseases* **226**, S79-S86.
- [37] **Fleming DM and Elliot AJ** (2007) The management of acute bronchitis in children. *Expert Opinion on Pharmacotherapy* **8**, 415-426.
- [38] **Min N, et al.** (2021) An epidemiological surveillance of hand foot and mouth disease in paediatric patients and in community: A Singapore retrospective cohort study, 2013-2018. *PLoS Negl Trop Dis* **15**, e0008885.
- [39] **Gonzalez G, et al.** (2019) Enterovirus-Associated Hand-Foot and Mouth Disease and Neurological Complications in Japan and the Rest of the World. *International Journal of Molecular Sciences* **20**, 5201.


- 454 [40] **Osterback R, et al.** (2009) Coxsackievirus A6 and hand, foot, and mouth disease,
455 Finland. *Emerging Infectious Diseases* **15**, 1485-1488.
- 456 [41] **Chen L, et al.** (2019) Molecular surveillance of coxsackievirus A16 reveals the
457 emergence of a new clade in mainland China. *Archives of Virology* **164**, 867-874.
- 458 [42] **Khetsuriani N, et al.** (2006) Enterovirus surveillance--United States, 1970-2005.
459 *MMWR Surveillance Summaries* **55**, 1-20.
- 460 [43] **Anh NT, et al.** (2018) Emerging Coxsackievirus A6 Causing Hand, Foot and Mouth
461 Disease, Vietnam. *Emerging Infectious Diseases* **24**, 654-662.
- 462 [44] **Kamahora T, et al.** (1985) Oligonucleotide fingerprint analysis of coxsackievirus
463 A10 isolated in Japan. *Journal of General Virology* **66**, 2627-2634.
- 464 [45] **Chau NVV, et al.** (2024) Emerging enterovirus A71 subgenogroup B5 causing severe
465 Hand, Foot, and Mouth Disease, Vietnam, 2023. *Emerging Infectious Diseases* **30**,
466 363-367.
- 467 [46] **NHS.** Hand, foot and mouth disease (2024) Available at:
468 <https://www.nhs.uk/conditions/hand-foot-mouth-disease/> (accessed 4 November
469 2024).

470

471

472

Figure 1




473

474

Accepted Manuscript

475

Figure 2



476

477

Accepted Manuscript

478 **Table 1: Hand foot and mouth disease (HFMD) seasonal activity range**

Year	Mean weekly rate*	Standard deviation of the mean	Lower 95% CI	Upper 95% CI	minimum rate*	maximum rate* (during peak week)	Peak week number
2017	2.47	2.09	1.9	3.03	1.02	8.64	43
2018	2.32	2.6	1.62	3.03	0.86	9.88	43
2019	2.03	1.59	1.61	2.46	0.72	6.26	44
2020	0.27	1.01	0	0.54	0.08	3.36	7
2021	0.62	2.69	-0.1	1.35	0.09	10.53	41
2022	1.47	0.59	1.3	1.62	0.44	6.17	46

479 * Rate of HFMD consultations per 100,000 registered patients. Post Covid-19 pandemic
 480 years are highlighted in grey.

481

482 **Table 2. Epidemiological characteristics of GP consultations for hand foot and mouth**
 483 **disease (HFMD) in England, 2017-2022, presented as the annual number of HFMD GP**
 484 **consultations (annual incidence rate per 100,000). Post Covid-19 pandemic years are**
 485 **highlighted in grey.**

	2017	2018	2019	2020	2021	2022	Mean
Total cases	17,054	17,681	14,247	4,151	11,259	11,994	12,731
Annual incidence	155.4	159.5	126.0	34.8	96.9	99.8	112.1
Age (incidence)							
<1 year	1,852 (1,668.5)	1,973 (1,799.9)	1,494 (1,376.5)	512 (485.8)	1,114 (1,075.9)	1,248 (1,168.2)	1,365.5
1-4 years	12,020 (2,286.6)	12,642 (2,411.5)	10,168 (1,937.5)	2,790 (536.8)	8,424 (1,655.7)	8,693 (1,731.4)	9,122.8
5-14 years	1,679 (128.3)	1,671 (124.1)	1,447 (105.3)	484 (34.7)	823 (58.3)	1,356 (95.3)	1,243.3
15-44years	1,272 (28.7)	1,189 (26.2)	992 (21.3)	306 (6.4)	799 (16.4)	628 (12.6)	864.3
45-64 years	179 (6.3)	163 (5.6)	123 (4.2)	48 (1.6)	80 (2.6)	54 (1.8)	107.8
>65 years	52 (2.7)	43 (2.2)	23 (1.2)	11 (0.5)	19 (0.9)	15 (0.7)	27.2
Sex (incidence)							
Male (incidence)	9,250 (158.8)	9,609 (164.9)	7,744 (132.9)	2,168 (37.2)	6,278 (107.7)	6,572 (112.8)	6,936.8
Female (incidence)	7,803 (134)	8,072 (139.5)	6,503 (112.4)	1,983 (34.2)	4,980 (86)	5,422 (93.7)	5,793.8

Male to female ratio	1.2	1.2	1.2	1.1	1.3	1.2	1.2
-----------------------------	-----	-----	-----	-----	-----	-----	-----

486 **Total cases include records with unknown age*

487

488

Accepted Manuscript